TCGA-OR-A5JZ-01
Adrenocortical Carcinoma · Adrenocortical Carcinoma · Adrenocortical Carcinoma, Usual Type
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MITOTIC_SPINDLE+0.401
- PROTEIN_SECRETION+0.384
- INTERFERON_GAMMA_RESPONSE+0.284
- APOPTOSIS+0.265
- ALLOGRAFT_REJECTION+0.263
- G2M_CHECKPOINT+0.254
- IL6_JAK_STAT3_SIGNALING+0.234
- COMPLEMENT+0.220
- E2F_TARGETS+0.214
- HYPOXIA+0.206
Top 10 suppressed
- CHOLESTEROL_HOMEOSTASIS-0.388
- MYC_TARGETS_V2-0.385
- OXIDATIVE_PHOSPHORYLATION-0.338
- WNT_BETA_CATENIN_SIGNALING-0.290
- NOTCH_SIGNALING-0.257
- PANCREAS_BETA_CELLS-0.244
- PEROXISOME-0.217
- MYC_TARGETS_V1-0.201
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.193
- MYOGENESIS-0.139
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-HD-7229-01A-11R-2016-07 | — | — | 0.790 |
| 2 | ad9039cd-cacc-43f3-8cc1-9a6af5d39e6f | — | — | 0.764 |
| 3 | TCGA-55-8089-01A-11R-2241-07 | — | cohortA1 | 0.727 |
| 4 | TCGA-55-6712-01A-11R-1858-07 | — | cohortA1 | 0.726 |
| 5 | 25400212-48de-48a9-96d3-2fc2ee23fd41 | — | — | 0.717 |
| 6 | 6a43f966-cb2b-47ee-b0f4-c269707daa88 | — | — | 0.715 |
| 7 | SJEPD030232_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.710 |
| 8 | 20ca78ce-1972-4f55-81f2-22683da33c66 | — | — | 0.704 |
| 9 | SRR2016971 | — | — | 0.698 |
| 10 | TCGA-XF-A8HD-01A-11R-A36F-07 | — | — | 0.696 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MITOTIC_SPINDLE | 0.401 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.384 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.284 | Idelalisib | — uncovered |
| APOPTOSIS | 0.265 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.263 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.254 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.234 | Inavolisib | — uncovered |
| COMPLEMENT | 0.220 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.214 | Inavolisib | — uncovered |
| HYPOXIA | 0.206 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.192 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.184 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.180 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.161 | Inavolisib | — uncovered |
| COAGULATION | 0.142 | Binimetinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.141 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.128 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.123 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.120 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.120 | Inavolisib | — uncovered |